Specialized in biopharmaceutical technologies designed to promote the development of cancer immunotherapies and cancer diagnostics

With effect from 1 October 2011, BioNTech AG Mainz will be a member of the MAINZ RESEARCH ALLIANCE. The enterprise thus joins the Mainz institutes of higher education, the Max Planck Institutes, the Academy of Science and Literature, the Institute of European History, the Roman-Germanic Central Museum, the Natural History Museum and other research institutes and research-driven enterprises in a network of what will be 21 organizations striving to achieve greater integration in order to promote the business and research hub that is the city of Mainz.

The immunological research undertaken in Mainz has enjoyed an excellent worldwide reputation for the past 30 years. The special interests of BioNTech AG, a spin-off organization of Johannes Gutenberg University Mainz, are biopharmaceutical technologies designed to help develop readily tolerated cancer immunotherapies and cancer diagnostics. The focus is on inoculation-based techniques that can be used to stimulate patients' endogenous immune systems for the targeted treatment of a wide range of cancer disorders. The company has an extensive database of cancer-specific target structures and is using proprietary technology platforms to develop drugs specifically designed to zero in on these structures.